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Phosphoinositide 3-kinase (PI3K)/Akt has
emerged as an important pathway in regulating
the signaling of many fundamental biological
processes, such as cell proliferation, survival and
apoptosis, glucose metabolism, ribosomal func-
tion, gene transcription, and cell migration, via
phosphorylation of a variety of substrates by the
crucial serine/threonine kinase Akt. Dysregulation
of the PI3K/Akt pathway is associated with the
development of many human malignancies.
Constitutive activation of the PI3K/Akt pathway
occurs in tumor cells via several mechanisms,
such as oncogene activation, gene amplification,
and inactivation of tumor suppressors. Activated
Akt contributes to tumor progression by modulat-
ing the function of numerous substrates related
to the regulation of cell proliferation, antiapopto-
sis and angiogenesis, and therefore, is a valid target
for anti-cancer therapy. PI3K/Akt signaling plays
a major role not only in tumor growth, but also in
the potential response of tumors to anti-cancer
treatment. Accumulating evidence has indicated
that activation of Akt promotes acquired resis-
tance to treatment with radiation, chemotherapy,
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Induction of Akt Activity by Chemotherapy
Confers Acquired Resistance
Wei-Chien Huang,1,2* Mien-Chie Hung1,2,3*
Resistance to chemotherapy is a major cause of treatment failure in human cancer. Accumulating evidence
has indicated that the acquisition of resistance to chemotherapeutic drugs involves the activation of the
PI3K/Akt pathway. Modulating Akt activity in response to chemotherapy has been observed often in
chemoresistant cancers. The potential molecular mechanisms by which chemotherapeutic agents activate
the PI3K/Akt pathway are emerging. Activation of this pathway evades the cytotoxic effects of chemother-
apeutic agents via regulation of essential cellular functions such as protein synthesis, antiapoptosis, sur-
vival and proliferation in cancer. How chemotherapeutic agents induce Akt activation and how activated
Akt confers chemoresistance through regulation of signaling networks are discussed in this review. Combining
PI3K/Akt inhibitors with standard chemotherapy has been successful in increasing the efficacy of chemother-
apeutic agents both in vivo and in vitro. Several small molecules have been developed to specifically target
PI3K/Akt and other components of this pathway, which in combination with chemotherapy may be a
valid approach to overcome therapeutic resistance. We propose several feedback and feedforward regulatory
mechanisms of signaling networks for maintenance of the Akt activity for cell survival. These regulatory
mechanisms may limit the efficacy of PI3K/Akt-targeted therapy; therefore, disruption of these mechanisms
may be an effective strategy for development of novel anti-cancer therapies. [J Formos Med Assoc 2009;
108(3):180–194]
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and/or targeted therapy. Therefore, specific inhi-
bition of Akt activation may be a valid approach
to treat human malignancies and overcome the
resistance of cancer cells to anti-cancer therapy.
Here, we discuss mainly the underlying mech-
anism of Akt activation for the acquisition of
chemoresistance.
PI3K/Akt Activation in Tumors
The PI3K/Akt pathway is activated initially at the
cell membrane, where the signals for pathway 
activation are propagated through PI3K. PI3K is
composed of a catalytic subunit (p110) and an
adapter/regulatory subunit (p85). It is activated
by receptor tyrosine kinases (RTKs) such as epider-
mal growth factor receptor (EGFR) and insulin-
like growth factor-1 receptor (IGF-1R), cell
adhesion molecules such as integrins, G-protein-
coupled receptors (GPCRs), and oncogenes such
as Ras. Once activated, PI3K is responsible for
the phosphorylation of plasma membrane lipid
phosphatidylinositol-4,5-bisphosphate at the 3
position of its inositol ring, to generate the biolog-
ically active molecule phosphatidylinositol-3,4,5-
trisphosphate [PI(3,4,5)P3]. Upon generation, PI
(3,4,5)P3 recruits 3-phosphoinositide-dependent
kinase 1 (PDK1) and serine/threonine kinase Akt
to the cell membrane, where they are subsequently
activated, via binding to their pleckstrin homol-
ogy (PH) domains. The tumor suppressor PTEN
(phosphatase and tensin homolog deleted on
chromosome 10) antagonizes PI3K by dephos-
phorylating PI(3,4,5)P3, thereby blocking trans-
location and activation of PDK-1 and Akt.
The Akt kinase family consists of three struc-
turally similar isoforms, Akt1, -2 and -3, which are
expressed in most tissues.1 Activation of Akt1 oc-
curs through two crucial phosphorylation events.
Upon recruitment to the cell membrane via bind-
ing to PI(3,4,5)P3 with its PH domain, Akt1 is
initially activated through phosphorylation at
T308 in the catalytic domain by PKD1.2,3 For its
full activation, a subsequent phosphorylation at
S473 in the hydrophobic motif is required, which
can be mediated by several kinases such as
PDK1,4,5 integrin-linked kinase,6,7 Akt itself,8
DNA-dependent protein kinase,9,10 or mammalian
target of rapamycin (mTOR).11,12 Akt2 and Akt3
are also phosphorylated at the homologous
residues, and thereby are activated by the same
mechanism. Structural features of phosphorylated
and non-phosphorylated Akt proteins have been
reviewed previously.13–15
Aberrant activation of PI3K/Akt signaling
pathways has been implicated in many cancers
through several mechanisms.14–16 As described
above, PI3K/Akt signaling is initiated as a result
of activation of RTKs or GPCRs. Since cell surface
receptors are commonly overexpressed or consti-
tutively activated in a large number of human
cancers, downstream PI3K/Akt signaling is often
activated as a result. One of the most extensively
studied examples is the overexpression of erbB2
that is achieved by strong activation of PI3K/Akt
in breast and other cancers. In addition to RTKs,
other upstream molecules, such as protein kinase
C (PKC), SHP1, Rac, Ras, Rho and Src, have been
found to enhance PI3K/Akt activity in some
human cancers.16,17
Dysregulation of the PI3K/Akt pathway in
cancer cells also occurs because of gene amplifi-
cation or mutations in the components of the
pathway. The gain function of PI3K mutations has
been frequently observed in many human cancers,
such as ovarian, breast, gastric and hepatocellular
carcinoma.18 Active mutations of PI3KCA, the
gene that encodes the p110a catalytic subunit of
PI3K, have been observed in many cancers in-
cluding, colorectal, gastric, breast, lung, ovarian,
hepatocellular and thyroid cancer, glioblastoma,
and acute leukemia.19–26 Amplification and over-
expression of PI3KCA have also been found in
several other types of cancer, including cervical,
gastric, ovarian and breast cancer, through a large-
scale mutational analysis.27–31 The amplification
of Akt isoforms has been detected in a number of
human cancers, including gastric carcinoma, glio-
blastoma, head and neck squamous carcinoma,
pancreatic, ovarian, prostatic and breast cancer.32–38
The tumor suppressor PTEN, an antagonist of
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PI3K, is also frequently mutated or lost in pri-
mary glioblastoma, breast, lung and melanoma
biopsies.28,39–42 The elevated Akt activity caused
by these mechanisms is correlated with progres-
sive outcome and poor prognosis in some human
cancers.41,43,44
Akt and PTEN Status Determines
Intrinsic Sensitivity to Chemotherapy
Akt is considered to be a molecular “crutch” that
cancer cells rely on early to escape cell death
once they are exposed to toxic stimuli. Aberrant
activation of Akt in most types of cancer has
been found to correlate with poor prognosis and
resistance to various anti-cancer therapies.45 In a
series of studies in human pancreatic adenocarci-
noma and breast cancer cells that have constitu-
tively active high Akt activity, treatment with
gemcitabine, a nucleoside analog, failed to affect
Akt activity or induce cell death.46–48 Activation
of Akt during preoperative chemotherapy for
esophageal cancer has been observed and is cor-
related with poor prognosis.49 Moreover, a retro-
spective review of a cohort of cervical squamous
carcinoma patients showed that immunohisto-
chemical staining of Akt phosphorylation was
significantly more frequent in the radiation-
resistance compared with the radiation-sensitive
group.50 pAkt signal is inversely correlated with
the clinical benefit of hormone therapy in breast
cancer patients.51,52 Furthermore, ectopic expres-
sion of the constitutively active form of Akt 
decreases the sensitivity of NSCLC A549 and
prostate cancer DU145 cells to cisplatin treat-
ment. Conversely, expression of the Akt domi-
nant negative mutant renders cisplatin-resistant
NSCLC A549 and human ovarian cancer A2780
cells susceptible to cisplatin treatment.53 These
clinical correlations between Akt activation and
poor treatment outcome and in vitro studies sug-
gest that the Akt signaling pathway is a common
mechanism for cellular insensitivity or acquired
resistance to various anti-cancer therapies. How-
ever, some studies have indicated that PI3K/Akt
activation is a favorable prognostic factor in
acute myelogenous leukemia and cholangiocar-
cinoma patients.54,55 The opposite functions of
different Akt isoforms may explain this discrep-
ancy.56 A survival analysis of early-stage breast
cancer has also revealed that Akt phosphoryla-
tion does not correlate with prognosis, nor pre-
dict resistance to anthracyclines,57 and PTEN status
provides the possible explanation for this dis-
crepancy. Terakawa et al reported that the loss of
PTEN, accompanied with Akt phosphorylation,
is a poor prognostic factor for patients with en-
dometrial cancer.58 Among patients undergoing
chemotherapy, PTEN-positive cases showed sig-
nificantly better survival rates than negative or het-
erogeneous cases.58 Overexpression of the PTEN
gene promotes the chemosensitivity of bladder
cancer cells and enhances the sensitivity of ma-
lignant glioma cells to irradiation.59,60 These
findings show that PI3K/Akt activity and PTEN
status may have a major impact on the sensitivity
and resistance to these treatments.
Chemotherapeutic Agents Induce Akt
Activation
In addition to the implication of aberrant Akt 
activation in determining the intrinsic resistance
of malignancies to chemotherapy, as described
above, several lines of evidence also indicate that
Akt activity can be modulated by chemothera-
peutic agents, which contributes to the develop-
ment of acquired resistance.
Cisplatin
As measured by Akt Thr308 and/or Ser473 phos-
phorylation and the phosphorylation state of its
endogenous substrate GSK3, activation of Akt
can be induced by cisplatin in several cancer cell
lines, including ovarian,61–63 breast,62 glioma and
pancreatic62 cancer cells. Constitutively active Akt
has also been found in cisplatin-selected chemore-
sistant lung,53 glioma63 and ovarian63,64 cancer cell
lines, compared with their sensitive parental coun-
terparts. Combined treatment with Ly294002, 
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a PI3K inhibitor, not only attenuates cisplatin-
dependent Akt activity, but also enhances 
cisplatin-induced cytotoxicity, which indicates that
Akt activation is caused by upstream activation
of PI3K and renders cancer cells more resistant to
cisplatin.62 Several mechanisms have been pro-
posed for mediating the cisplatin-induced PI3K/
Akt activation, as illustrated in the Figure. The
cisplatin-resistant NSCLC A549 cells, established
by stepwise exposure to increasing concentrations
of cisplatin, shows increases in Akt1 activity, pro-
tein and mRNA levels, and gene amplification
compared with its parental cells.53 The levels of
pAkt signals in human lung tumor tissues are 
inversely related to the cisplatin sensitivity of 
primary cultured lung cancer cells from the same
tumor tissues.53
In addition to Akt gene alterations, Tsang’s
group has shown that cisplatin is able to induce
both X-linked inhibitor of apoptosis (XIAP) and
Akt cleavage by activating caspase-3 in chemosen-
sitive (A2780-s and OV2008) but not in cisplatin-
resistant (A2780-cp and C13*) ovarian cancer
cells.61 Their data have also shown that overex-
pression of XIAP by sense adenoviral XIAP cDNA
infection increases pAkt content, which is associ-
ated with a decrease in cisplatin-induced apopto-
sis. Since XIAP is able to bind to and inhibit
caspase 3,65 the increased level and activity of 
Akt in cisplatin-resistant cells may result from
XIAP-mediated inhibition of caspase 3. However,
in the presence of LY294002, overexpression of
XIAP fails to increase Akt phosphorylation and
block cisplatin-induced apoptosis.61 These find-
ings indicate that upregulation of Akt activity by
XIAP may result from, not only the prevention of
caspase-3-mediated Akt cleavage, but also modula-
tion of upstream PI3K activity. However, it remains
to be investigated whether XIAP upregulates this
pathway by activating kinases (such as PI3K or
PDK1), deactivating phosphatases (such as SH2-
containing inositol polyphosphate-5-phosphatase
or PTEN), or both. Interestingly, this group has
also found that downregulation of XIAP by anti-
sense adenovirus increases the sensitivity of p53
wild-type C13* cells to cisplatin, but is unable to
induced apoptosis or increase cisplatin sensitivity
in cisplatin-resistant, p53-mutated A2780cp cells.66
This suggests that p53 status is a determinant of
XIAP- and Akt-mediated cisplatin resistance in
ovarian cancer cells.67 It has been demonstrated
that the induction of PTEN and reduction of
PI3KCA expression by p53 at the transcriptional
level leads to inhibition of Akt activity.68,69 Our
previous study has also shown that mouse double
minute 2 (MDM2)-dependent ubiquitination and
degradation of p53 is mediated by Akt, and is re-
quired for resistance to DNA-damaging agents.70
This raises the possibility that the increased levels
of XIAP and subsequent Akt activity in response
to cisplatin downregulate p53 expression, to form
a feedforward Akt activation loop via downre-
gulation of PTEN but upregulation of PI3KCA
expression (Figure).
Similar to this hypothetic model, Aurora-A
serine/threonine protein kinase, which is fre-
quently activated in epithelial malignancies, has
also been found to induce cell survival and
chemoresistance by activation of Akt through a
p53-dependent mechanism in ovarian cancer
cells. Aurora-A kinase can attenuate p53 DNA
binding and transcriptional activity via phosphor-
ylating its Ser215 residue.71 Ectopic expression of
Aurora-A abrogates p53-induced PTEN promoter
activity, and thereby leads to Akt activation that
confers cisplatin resistance.64 The involvement of
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Figure. Signaling network of cisplatin-induced Akt activation.
XIAP and Aurora-A kinase in the regulation of
p53 seems to be important for the Akt-mediated
acquired resistance of ovarian cancer to cisplatin.
However, the cross-talk among these molecules
in the cisplatin-resistant cancer cells remains to
be clarified.
Cisplatin-induced Akt activation has been
shown to rely on EGFR activity, which is upstream
of PI3K.62 Interestingly, cisplatin-induced phos-
phorylation of EGFR is accompanied by EGFR
internalization and ATM- or ATR-dependent activa-
tion of p38, which is known to occur as a result of
cisplatin-induced DNA damage.62,72,73 Inhibition
of p38 can attenuate EGFR internalization. Direct
phosphorylation of EGFR at T699 by p38 has
been identified as essential for cisplatin-induced
internalization of EGFR. Internalized EGFR can
form signaling complexes in endosomes, and in-
duces tyrosine phosphorylation and activation
of the p85 subunit of PI3K,74 which suggests that
p38-dependent internalization of EGFR induced
by cisplatin may drive PI3K/Akt activation through
phosphorylation of its p85 subunit.
Etoposide
Etoposide, a podophyllotoxin, has pleiotropic ac-
tions within cells, including inhibition of topoi-
somerase II, generation of reactive oxygen species,
and induction of DNA damage. Treatment with
etoposide can induce PI3K/Akt activity in gastric
cancer cells75,76 and NIH 3T3 fibroblast cell lines,77
which decreases the sensitivity to chemotherapy
via prevention of apoptosis. However, a mecha-
nistic connection between PI3k/Akt activation
and the actions of etoposide remains to be estab-
lished. EGFR activation signaling may contribute
to etoposide-induced Akt activity and chemoresis-
tance. Elevated peptide level of a heparin-binding
EGF-like growth factor (HB-EGF), a ligand of
EGFR, has been observed in etoposide-exposed
HeLa cells.78 A subset of EGF system ligands but
not receptors, including amphiregulin, HB-EGF
and epiregulin, has also been induced by etopo-
side in bladder cancer cell lines.79 Etoposide in-
creases the expression levels of these ligands via
stabilizing their mRNA by a mechanism that 
involves the 3’ untranslated region,78 but the pre-
cise mechanism awaits clarification. Activation
of EGFR by these ligands in response to etopo-
side treatment may drive Akt signaling to override
etoposide-induced apoptosis. Combined therapy
with etoposide and EGFR inhibitors has been re-
ported to have synergistic effects on induction of
apoptosis, further supporting this hypothetical
mechanism.80
In addition to EGF–EGFR autocrine activation,
increased adhesion to the local environment may
also account for the protection of tumor cells from
etoposide-induced apoptosis via PI3k/Akt sig-
naling. Activation of β1 integrin by extracellular
matrix81 and progenitor cell marker NG2/MPG82
has been found to activate PI3k/Akt signaling,
and to prevent etoposide-induced caspase-3 acti-
vation and subsequent apoptosis in small cell lung
cancer (SCLC) and glioblastoma cells. Although
the elevated Akt activity and integrin-dependent
adhesion have been observed in etoposide-resistant
SCLC cells,83 whether and how etoposide activates
integrin remain unclear.
Several other molecules that can drive PI3k/Akt
activation have also been implicated in chemore-
sistance to etoposide. High levels of plasminogen
activator inhibitor (PAI-1) in tumors are associated
with poor prognosis in several cancer types.84,85
PAI-1 has been shown to stimulate angiogenesis,86
mediate/stimulate cell migration,87 and modulate
cell adhesion.88 Silencing of PAI-1 by RNA inter-
ference in wild-type fibrosarcoma cells decreases
the level of active Akt. This is accompanied by sen-
sitization of the cells to etoposide-induced cell
death, which suggests that PAI-1 influences sen-
sitivity to etoposide-induced apoptosis through
the PI3K/Akt cell survival pathway by acting 
upstream of PI3K and Akt.89 Secretion of neu-
ropeptide calcitonin (CT) from prostate cancer
and activation of CT receptor (CTR) are associated
with tumor progression. Addition of CT signi-
ficantly induces Akt activation and attenuates
etoposide-induced apoptosis in prostate cancer
cell lines. Pretreatment with PI3K inhibitor LY
294002 can resensitize tumor cells to etoposide,
which indicates that CTR activation confers
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chemoresistance to etoposide via activating PI3k/
Akt and downstream pathways.90 Although au-
tocrine regulation of PAI-1 and CT has been
demonstrated to be involved in etoposide resis-
tance through activation of the PI3k/Akt pathway,
whether etoposide has a role in the secretion of
PAI-1 and CT remains to be examined.
Paclitaxel
Activation of Akt by paclitaxel was observed firstly
in ovarian cancer cells. Induction of activity and
phosphorylation of Akt in response to paclitaxel
treatment was detected at 30 minutes and, reached
a plateau at 3 hours, and declined thereafter. This
transient activation of Akt by paclitaxel mediates
the following inhibitory regulation and phosphor-
ylation of Raf-1, and prevents taxol-induced apo-
ptosis.91 Constitutive activation of Akt has also
been found in acquired taxol-resistant HNE1-T3
cells, which are derived from human nasopha-
ryngeal carcinoma (NPC) cell line HNE1 by ex-
posure to increasing concentrations of taxol.92
Interestingly, upregulation of TWIST, a basic helix–
loop–helix transcription factor, has been found
to mediate the development of acquired resis-
tance to paclitaxel in an Akt-dependent manner.93
Inactivation of TWIST by siRNA can lead to the
suppression of Akt phosphorylation and decreased
cell viability in response to taxol,92 which sug-
gests that the increased TWIST in NPC cells may
be able to activate the Akt pathway, which in turn,
attenuates paclitaxel-induced apoptosis. More-
over, the increased TWIST protein levels are also
associated with another microtubule-targeting
anticancer drug, vincristine, in several types of
human cancer, including nasopharyngeal, blad-
der, ovarian and prostate cancer.93 This indicates
that TWIST/Akt may play a central role in the 
resistance to microtubule-disrupting agents. The
TWIST-induced transcriptional expression of Akt2
is further proposed to mediate acquired resis-
tance to taxol.94 Although the precise molecular
mechanism is not clear, EGFR activation may be
involved in the paclitaxel-induced increase in
TWIST level and subsequent Akt expression. A con-
comitant increase in EGFR and Akt activity has
been observed in paclitaxel-treated lung and
pancreatic cancer cells,95,96 and determines the
response to combined gefitinib/chemotherapy
treatment.95 A recent study has indicated that ac-
tivation of EGFR induces STAT3-mediated TWIST
gene expression,97 which suggests that paclitaxel-
induced EGFR activation, in addition to directly
driving downstream Akt activation signaling, may
also indirectly increase Akt protein level via TWIST-
dependent gene upregulation.
Doxorubicin and daunorubicin
Elevated Akt activity in response to the anthracy-
clines doxorubicin and daunorubicin has been
observed in gastric cancer,75 leukemic cells,98,99
and breast cancer.100 Pretreatment with PI3K in-
hibitors or overexpression of PTEN attenuates the
Akt activity and apoptosis induced by doxoru-
bicin, which indicates that the PI3K/Akt pathway
mediates the acquisition of resistance to doxoru-
bicin.75,98,100 Doxorubicin-induced Akt phos-
phorylation, in contrast to paclitaxel-induced
transient Akt activation, occurs slowly at 
6 hours after treatment, and is sustained contin-
uously for 48 days,75,99 which implies that
PI3K/Akt activity is regulated at the transcrip-
tional level.
Increased expression of forkhead transcription
factor FOXO3a is involved in Akt activation and
confers resistance to the cytotoxic effects of doxo-
rubicin.99 The mammalian FOXO family of tran-
scription factors mediates expression of numerous
genes that are related to cell proliferation, apo-
ptosis and differentiation, and phosphorylation
by Akt results in their nuclear exclusion and pre-
vents their transcriptional activity. Hu and Hung
provided evidence that chronic exposure of
chronic myelogenous leukemia (CML) cells to
doxorubicin increases nuclear accumulation of
FOXO3a.101 Nuclear FOXO3a targets gene ex-
pression of the PI3K catalytic subunit p110α, and
knockdown of p110α reduces Akt activation and
sensitizes tumor cells to doxorubicin. The results
of Hu and Hung suggest that chronic activation
of FOXO3a by doxorubicin in CML cells can en-
hance survival through feedback hyperactivation
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of Akt by increasing p110α expression.101 Since
FOXO3a is inactivated and excluded from the
nucleus by Akt, the nuclear accumulation of
FOXO3a and induction of PI3K/Akt activity are
transient. However, this homeostatic mechanism
seems to be disrupted in doxorubicin-resistant
cells, which results in constitutive nuclear expres-
sion of FOXO3a and consequent PI3k/Akt acti-
vation. The mechanism by which doxorubicin
treatment allows FOXO3a to evade Akt-depend-
ent cytoplasmic sequestration and inactivation
remains to be explored. Nuclear FOXO3a can in-
duce apoptosis via mediating expression of several
proapoptotic genes, such as Fas ligand, Bim and
tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL),101 which contrasts with the pro-
survival effect of induced p110α expression and
subsequent Akt activation in doxorubicin-
resistant cells. It is not yet clear whether this non-
traditional Akt/FOXO3a relationship causes the
doxorubicin-resistant phenotype.
More recently, two peaks of Akt activation in
response to doxorubicin and γ-irradiation have
been observed: a more prominent peak after 30
minutes treatment with doxorubicin treatment
and a smaller peak at 4 hours. The doxorubicin-
induced Akt activation was abolished in DNA-
PKcs−/− MEFs over time, which suggests that
DNA-PK activated by DNA double strand break-
age induces Akt activation for cell survival after
exposure to DNA-damaging agents.102,103
Molecular Mechanism of Akt Conferring
Drug Resistance
The action of most chemotherapeutic agents is
thought to be mainly associated with their ability
to induce apoptosis, which involves cytochrome
c release and the apoptosome-catalyzed caspase
cascade. The failure of drug-induced apoptosis
appears to be a critical cause of chemoresistance.
Upon activation, PI3K/Akt signaling confers 
acquired resistance to chemotherapy through 
its antiapoptotic effects, via phosphorylation of
several downstream targets.
p53-independent antiapoptosis
Most directly, active Akt is thought to inhibit apo-
ptosis by phosphorylating molecules upstream
and downstream of mitochondrial perturbation.
Phosphorylation of proapoptotic Bcl-2 family
members such as Bad at Ser136,104,105 Bax at
Ser184,106 and Bim(EL) at Ser87107 has been
shown to decrease their ability to hold mitochon-
dria in an open configuration, and thereby reduce
cytochrome c release. Downstream to cytochrome
c release, Akt can phosphorylate caspase-9 at
Ser196 to inhibit its protease activity, which acti-
vates executioner caspase 3.108 In contrast, Akt also
reduces cytochrome c release through regulation
of antiapoptotic Bcl-2 homologous Mcl-1 at the
post-translational level.109 Phosphorylation of
Mcl-1 at Ser159 by GSK-3 leads to ubiquitinyla-
tion and degradation of Mcl-1, inducing Bax and
Bak oligomerization in a Bim-dependent manner
for mitochondrial outer membrane permeabiliza-
tion and release of cytochrome c. Increased Akt ac-
tivity can abrogate this apoptotic process through
inhibitory phosphorylation of GSK-3. Moreover,
upregulation and phosphorylation at Thr34 of
survivin, an inhibitor of apoptosis protein (IAP),
in an Akt-dependent manner has also been ob-
served in cisplatin-resistant SCLC cells, and pro-
tect cells from cisplatin-induced apoptosis.110 The
survivin phosphorylation at Thr34 is known to
be mediated by the cdc2–cyclin B1 complex.111
Therefore, whether Akt phosphorylates survivin
directly or by indirectly activating cdc2–cyclin B1
or other kinases awaits investigation.
p53-dependent antiapoptosis
Akt exerts indirect inhibition of apoptosis through
regulation of transcription factors. Transcription
factor p53 is the most important regulator of
apoptosis in response to DNA-damaging agents
such as cisplatin.112 p53 induces apoptosis and
controls cytochrome c release via transcriptional
upregulation of gene products such as Bax, p53-
upregulated modulator of apoptosis (PUMA) and
NOXA,113–116 and transcriptional repression of
gene products such as Bcl-2 and survivin.115,117,118
Rapid stabilization and activation of p53 in 
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response to DNA-damaging agents occur through
its site-specific phosphorylation, which attenuates
bindings of p53 to proto-oncoprotein MDM2,
and E3 ligase mediates the ubiquitination of 
p53 and facilitates its proteasomal degradation. 
We, and others, have reported that activated Akt
physically associates with and phosphorylates
MDM2 at Ser166 and Ser186, in response to HER2
overexpression and other growth factors.70,119–124
Phosphorylation of MDM2 enhances its nuclear
localization, and thus increases p53 ubiquiti-
nation and degradation.70,124 Furthermore, up-
regulation of PTEN by the synthetic compound
3,5-bis-(2-fluorobenzylidene)piperidin-4-one can
resensitize cisplatin-resistant ovarian cancer cells
through induction of G2M arrest and apoptosis
by attenuating Akt- and MDM2-mediated p53
downregulation.125 Inhibition of p53 phospho-
rylation and nuclear accumulation and subse-
quent p53-mediated PUMA upregulation by Akt
have also been observed in cisplatin-resistant
ovarian cancer cells.126 These findings indicate
that Akt activation confers chemoresistance, in
part, through downregulation of p53 via enhanc-
ing MDM2 activity and subsequent control of
p53-regulated gene expression. p53 also regulates
apoptosis through a transcription-independent
mechanism. p53 protein can directly induce per-
meabilization of the outer mitochondrial mem-
brane by forming complexes with the protective
Bcl-xL and Bcl2 proteins. This results in cyto-
chrome c and Smac release,127,128 which was ob-
served in cisplatin-treated cells.129 Akt has also
been reported to attenuate mitochondrial p53 ac-
cumulation and Smac/cytochrome c/Omi release,
thereby contributing to cisplatin resistance.129
However, whether the inhibition of p53 accumu-
lation in mitochondria by Akt is also mediated
in an MDM2-dependent manner remains to be
examined.
Other transcriptional functions in
antiapoptosis
In addition to p53, Akt also regulates other tran-
scription factors such as cAMP-responsive element-
binding protein (CREB), members of the Forkhead
family, and nuclear factor (NF)-κB to increase
antiapoptotic and pro-survival gene expression
or decrease proapoptotic gene expression. Akt
activates CREB via phosphorylation of its Ser133
residue.130 CREB can induce Bcl-2 expression in
a myriad of cell types.131,132 Loss of PTEN or over-
expression of Akt has also been found to induce
CREB-mediated Bcl2 expression, which contributes
to chemoresistance of advanced prostate cancer
cells.133 Akt also inhibits the expression of proapo-
ptotic Bcl2 family members through inactivation
of FOXO proteins. Akt-dependent phosphoryla-
tion of FOXO proteins occurs in the nucleus, and
facilitates their interactions with 14-3-3, which
displace FOXO transcription factors from target
genes and trigger their export from the nucleus.
Through this mechanism, Akt attenuates FOXO-
mediated transcription of target genes that promote
apoptosis, cell-cycle arrest and metabolism.134 Akt-
dependent control of NF-κB gene transcription has
also been implicated in Akt-mediated antiapo-
ptotic or survival signaling.135–138 The involvement
of Akt-mediated NF-κB activation in chemoresis-
tance has been observed in various human can-
cers75,79,139–143 The antiapoptotic activities of
NF-κB result from transactivation of antiapo-
ptotic factors such as IAP proteins, cFLIP and Bcl-
xL.110,144–149 In addition to the regulation of
antiapoptotic gene expression, Akt-dependent NF-
κB activation also mediates the transactivation of
transmembrane transport pump P-glycoprotein,
which causes efflux of chemotherapeutic agents
from cells and is an important system that secures
multidrug resistance of neoplastic cells.139,142,143
Caspase-independent antiapoptosis
Akt activation also mediates the inhibition of
caspase-independent apoptosis. Cisplatin induces
the mitochondrial release and nuclear transloca-
tion of apoptosis-inducing factor (AIF), a mediator
of caspase-independent apoptosis, and AIF-
dependent apoptosis. Activation of Akt attenu-
ates the cisplatin-induced mitochondrial release
and accumulation of AIF and apoptosis in chemo-
sensitive ovarian cancer cells, whereas inhibition
of Akt activity facilitates these effects and sensitizes
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chemoresistant cells to AIF-dependent, cisplatin-
induced apoptosis.150
Cell growth
Another important function of Akt in chemore-
sistance is its role in promoting cell growth. Akt
is linked to the survival pathway of mammalian
target of rapamycin (mTOR), a serine/threonine
kinase that is implicated in protein synthesis
control, which can be potently inhibited by the
immunosuppressant rapamycin. Activation of
mTOR enhances tumor growth and chemoresis-
tance via inhibiting cell death pathways such as
apoptosis and autophagy.151–153 Akt activates
mTOR complex 1 (mTORC1; or mTOR-raptor
complex) indirectly by inhibiting phosphorylation
of tuberous sclerosis complex 2 (also known as
tuberin), thereby allowing Ras-related small G
protein (Rheb)-GTP to activate mTORC1 signal-
ing.134 Survival results from mTORC1, which
drives translation by activation of ribosomal S6
kinase (p70S6K) and release of eukaryotic initia-
tion factor 4E by phosphorylating its inhibitor
binding protein 4E-BP1.154,155 By controlling
protein synthesis, p70S6K and 4E-BP1 also control
cell growth and hypertrophy,156 which are impor-
tant processes for tumor growth.
Combined Therapy with Chemotherapy
and PI3K/Akt/mTOR Inhibitors, and
Possible Limitations
Since deregulated signaling through activated
PI3K/Akt/mTOR pathways contributes to the de-
velopment of cancer resistance to chemotherapy,
targeting PI3K/Akt/mTOR activation has emerged
as a promising combinatory approach with con-
ventional chemotherapy for successful treatments
of cancer. Combinations of pathway inhibitors,
including PI3K inhibitors LY294002 and wort-
mannin, Akt inhibitors perifosine and tricirib-
ine, and PIAs, and mTOR inhibitors rapamycin
and its analogs, with various types of chemother-
apy have been investigated extensively in preclin-
ical studies, and have shown synergistic efficacy
with chemotherapeutic agents in vivo. An update
on the clinical progress and efficacy of combina-
tory therapies with PI3K/Akt/mTOR inhibitors has
been presented in a review.157 Only a few clinical
trials with Akt inhibitor perifosine and mTOR in-
hibitors rapamycin, CCI-779 and RAD-001 have
been reported, while no clinical trials using PI3K
inhibitors have been published. Whether any of
these compounds might be truly useful in the
management of patients with cancer awaits fur-
ther study. Here, several feedback and feedforward
regulatory mechanisms have been proposed to
maintain homeostatic Akt activation for cell sur-
vival. These regulatory mechanisms may limit the
efficacy of PI3K/Akt-targeted therapies. Therefore,
disruption of this regulation of Akt activity may be
an effective strategy for the development of novel
cancer therapies. Another possible limitation re-
sult from the development of cross-talk with other
pathways. Hyperactivation of mitogen-activated
protein kinase (MAPK) signaling has been ob-
served when cells are treated with the PI3K in-
hibitor LY294002, which indicates that, even with
inhibition of PI3K/Akt pathways, MAPK activation
compensates the survival signaling while Akt sig-
naling is inhibited.158 The other predicted com-
pensator will be IKK, since our own studies and
those of others have indicated that these three
oncokinases, including Akt, ERK and IKK, exert a
concerted regulation on several substrates such as
TSC and FOXO3a, and jointly regulate the survival-
related signaling network.159 This suggests that
signaling cross-talk between the PI3K/Akt and
other pathways occurs during treatment, which
highlights the potential pitfall of targeting the
PI3K/Akt pathway in cancer therapy.
Conclusion
The PI3K/Akt pathway orchestrates multiple cell
responses including mitogenic signaling, cell sur-
vival and growth, metabolic control, and tumor
metastasis. Aberrant PI3K/Akt activation, which
is believed to be a major component contribut-
ing to the intrinsic insensitivity of cancer cells to
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chemotherapy, is caused by genetic alterations.
Accumulating evidence indicates that activation
of the PI3K/Akt pathway is also a consequence of
administration of many types of chemotherapeu-
tic agents. The chemotherapy-induced PI3K/Akt
activation may account for the major limitation
of successful and durable clinical responses to
chemotherapy, and for the development of ac-
quired resistance. Therefore, knowledge of PI3K/
Akt activation by chemotherapeutic agents may
have important clinical implications in cancer
chemotherapy. The important issues to be ad-
dressed are whether PI3K/Akt activation is a gen-
eral determinant of acquired resistance to various
chemotherapeutic agents, and whether activation
of other oncokinases in concert with Akt also
participates in the development of chemoresis-
tance. Such clinical data are almost missing now-
adays. Future work may identify the mechanisms
involved in activation of PI3K/Akt by chemo-
therapy, and provide new targets for combination
therapy aimed at circumventing or decreasing
chemoresistance.
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